Summary Comments
- Most frequently detected viruses in September (all age groups):
- Rhino/Enterovirus: 27.5%
- Rhinovirus: 17.2%
- Metapneumovirus: 12.5%
- Epidemiological Week 1–39:
- SARS-CoV-2: Stable over last four weeks
- Influenza A: Peaked at 43.6% (week 20), declined to 0.5% (week 39)
- Influenza B: Peaked at 26% (week 31), declined to 4.8% (week 39)
- RSV: Peaked at 27.8% (week 13), declined to 2.4% (week 39)
Respiratory Viral Multiplex PCR and SARS-CoV-2 PCR: All Age Groups
August 2024:
- Rhino/Enterovirus: 29%
- Rhinovirus: 20.4%
- Metapneumovirus: 9.7%
- SARS-CoV-2: 6.3%
- Parainfluenza 1–4: 9.3%
- Adenovirus: 5.2%
- Influenza A: 1.9%
- Influenza B: 1.7%
- RSV: 2.7%
September 2024:
- Rhino/Enterovirus: 27.5%
- Rhinovirus: 17.2%
- Metapneumovirus: 12.5%
- SARS-CoV-2: 6.4%
- Parainfluenza 1–4: 6.5%
- Adenovirus: 1%
- Influenza A: 1%
- Influenza B: 0.5%
- RSV: 2.4%
Atypical Bacterial Pathogens (Weeks 1–39)
Detected Pathogens:
- B. pertussis, M. pneumoniae, C. pneumoniae
- 1 case of Legionella pneumophila in September
Age Distribution:
Bordetella pertussis:
- 0–6 months: 15%
- 6–12 months: 6%
- 1–5 years: 32%
- 6–12 years: 19%
- 13–18 years: 2%
- 19–64 years: 24%
65 years: 2%
Mycoplasma pneumoniae:
- 0–6 months: 2%
- 6–12 months: 3%
- 1–5 years: 27%
- 6–12 years: 29%
- 13–18 years: 4%
- 19–64 years: 13%
65 years: 2%
Chlamydia pneumoniae:
- 0–6 months: 3%
- 6–12 months: 4%
- 1–5 years: 46%
- 6–12 years: 28%
- 13–18 years: 8%
- 19–64 years: 13%
65 years: 1%
Paediatric Respiratory Viral Multiplex PCR Data (Ages 0–12)
<1 Year Age Group
August 2024:
- Rhino/Enterovirus: 47.3%
- Rhinovirus: 42.4%
- Parainfluenza 1–4: 17.6%
- Metapneumovirus: 14.8%
- SARS-CoV-2: 10.7%
- Adenovirus: 13.5%
- Influenza A: 0.8%
- Influenza B: 0.7%
- RSV: 3.6%
September 2024:
- Rhino/Enterovirus: 42.4%
- Rhinovirus: 35%
- Parainfluenza 1–4: 17.5%
- Metapneumovirus: 14%
- SARS-CoV-2: 11.3%
- Adenovirus: 13.5%
- Influenza A: 1.1%
- Influenza B: 0.4%
- RSV: 3.6%
1–5 Year Age Group
August 2024:
- Rhino/Enterovirus: 48.6%
- Rhinovirus: 35.8%
- Parainfluenza 1–4: 15%
- Metapneumovirus: 18.1%
- Adenovirus: 17.2%
- SARS-CoV-2: 11.5%
- Enterovirus: 18.1%
- Influenza A: 1.2%
- Influenza B: 0.6%
- RSV: 1.1%
September 2024:
- Rhino/Enterovirus: 48.6%
- Rhinovirus: 35.1%
- Parainfluenza 1–4: 15.6%
- Metapneumovirus: 18.1%
- Adenovirus: 17.2%
- SARS-CoV-2: 10.7%
- Enterovirus: 16.6%
- Influenza A: 2.9%
- Influenza B: 0.6%
- RSV: 0.3%
6–12 Year Age Group
August 2024:
- Rhino/Enterovirus: 40.4%
- Rhinovirus: 36.1%
- Influenza B: 38.7%
- SARS-CoV-2: 7%
- Parainfluenza 1–4: 6.2%
- Adenovirus: 9.6%
- RSV: 0.7%
September 2024:
- Rhino/Enterovirus: 42.8%
- Rhinovirus: 37.7%
- Influenza B: 25.4%
- SARS-CoV-2: 8.1%
- Parainfluenza 1–4: 7.3%
- Adenovirus: 7.6%
- RSV: 0.3%
Highlights by Age Group (September 2024)
- <1 year:
- Metapneumovirus: 19.4%, Parainfluenza: 17.6%
- RSV and Influenza B continued to decrease
- 1–5 years:
- Increase in Metapneumovirus (18.1%), Adenovirus (17.2%), Parainfluenza (15%)
- RSV and Influenza B decreasing
- 6–12 years:
- Influenza B still leading virus, despite decline (25.4%)
- High rates of Rhino/Enterovirus and Rhinovirus
Continue Reading